Vaccine Ingredients: SV40
Polio vaccines used in the late 1950s and early 1960s were contaminated with a virus called simian virus 40 (SV40). The virus was unknowingly present in monkey kidney cells used to grow the vaccine virus. Not much was known about SV40 at the time. This led to fear that people who received the contaminated vaccines would be harmed by their exposure to SV40.
About SV40
SV40 is a DNA virus in the polyomavirus family. The virus was first described by Drs. Maurice Hilleman and Bernice Eddy and their colleagues in 1960 when they detected it during vaccine safety testing. The vaccine viruses had been grown in monkey kidney cells contaminated with SV40. Because the contaminated vaccines were given to people, scientists quickly started studying SV40 in the lab. Animal studies suggested that infection could cause some cancers, increasing concerns about harm to those who received the contaminated vaccines.
An interesting aside related to this story is that Dr. Hilleman worked at the vaccine manufacturing company, Merck, and Dr. Eddy worked at the National Institutes of Health. Dr. Hilleman was able to report his findings, and the company stopped making their polio vaccine. However, while Dr. Eddy announced her findings at a conference in 1960, she was not allowed to publish them for two years as the government was concerned about the effects on the vaccine program.
On the go? Watch or listen.
Get a summary of the information on this page:
SV40 in vaccines
The vaccines contaminated with SV40 included:
- An inactivated adenovirus vaccine given to military recruits between 1961 and 1965
- Salk’s inactivated polio vaccine (IPV) used between 1955 and 1963
- Sabin’s live, weakened polio vaccine (OPV) used in clinical trials between 1959 and 1961
- An experimental live, weakened respiratory syncytial virus (RSV) vaccine (never licensed)
Most exposures came from IPV. About 98 million children and adults received this vaccine between 1955 and 1963. Between 10% and 30% of the doses were contaminated with SV40. About 100,000 military recruits received the contaminated adenovirus vaccine. About 10,000 people received OPV, but interestingly, these individuals did not develop immune responses to the virus in contrast to those who received IPV. Only about 100 adults received the contaminated RSV vaccine.
In 1961, the government required polio vaccine testing to ensure that future lots were not contaminated. However, previously approved lots of IPV that may have contained SV40 were used until early 1963.
Cell lines used to make vaccines after this situation occurred have been confirmed to be free of SV40. As such, no vaccines used in the U.S. since the early 1960s have been contaminated. This is not the case for vaccines used in some other countries where it took longer for them to stop using SV40-contaminated cells.
Health effects of SV40
When investigators studied SV40 virus, they found that it could cause cancer in animals in the lab. Cancers or tumors developed in the brain, lining of the lung, bones and lymph nodes.
When biopsy specimens were taken from people, SV40 viral DNA could sometimes be found in patients with cancers and tumors in the same tissues identified in animals:
- Mesothelioma, cells lining the lung
- Osteosarcoma, cells of the bone
- Non-Hodgkin’s lymphoma, cells of the lymph nodes
- Some brain tumors
Two points are important:
- Immune responses against SV40 have been found in people who did not receive the contaminated vaccines, suggesting that the virus continues to spread in other ways. Between 2 and 20 of 100 people tested have been found to have evidence of an SV40 infection.
- SV40 has been shown to cause cancer in animals, and it has been implicated in some cancers in people. However, inconsistent findings have made it difficult to determine whether there is a causal link between SV40 infection and development of these cancers.
Studies into SV40 and its role in some cancers continue.
SV40 in vaccines and health
Despite the questions about whether SV40 can cause some cancers, evaluations of the people who received the contaminated vaccines in the 1950s and 1960s have occurred over the decades since, and several findings are reassuring:
- SV40 was present in cancers of people who either had or had not received the contaminated polio vaccines.
- People with cancers who were born after 1963, when SV40 was no longer a contaminant of the polio vaccine, were found to have evidence for SV40 in their cancerous cells.
- Epidemiologic studies did not show an increased risk of cancers in those who received polio vaccine between 1955 and 1963.
Taken together, these findings do not support the hypothesis that SV40 virus contained in polio vaccines administered before 1963 caused cancers.
In addition, cells used to make U.S. vaccines since the early 1960s have been confirmed to not contain SV40, so this is not a concern related to today’s vaccines.
Summary
SV40 is a DNA virus that infects monkeys. The virus was identified in 1960 when it was found in monkey kidney cells used to make some vaccines. As a result, some people were accidentally exposed to this virus through vaccination, particularly people who received the inactivated polio vaccine between 1955 and 1963. While the virus has been shown to cause cancers and tumors in animals, the data related to causation are less clear in people and continue to be an area of scientific study. Importantly, when we consider vaccines, two points are important. First, the people exposed to SV40 in vaccines have been monitored, and they do not have an increased risk for cancer because of their exposure. Second, vaccines made in the U.S. have been confirmed to be free of SV40 since the early 1960s, so this is not a concern for families making vaccine decisions today.
References
Carroll-Pankhurst, C., E. A. Engels, H. D. Strickler, et al. “Thirty-five Year Mortality Following Receipt of SV40-Contaminated Polio Vaccine During the Neonatal Period.” British Journal of Cancer. 85 (2001): 1295–1297.
Engels, E. A., J. Chen, R. P. Viscidi, et al. “Poliovirus Vaccination During Pregnancy, Maternal Seroconversion to Simian Virus 40, and Risk of Childhood Cancer.” American Journal of Epidemiology. 160 (2004): 306–316.
Engels, E. A., H. A. Katki, N. M. Nielson, et al. “Cancer Incidence in Denmark Following Exposure to Poliovirus Vaccine Contaminated with Simian Virus 40.” Journal of the National Cancer Institute. 95 (2003): 532–539.
Engels, E. A., L. H. Rodman, M. Frisch, et al. “Childhood Exposure to Simian Virus 40-Contaminated Poliovirus Vaccine and Risk of AIDS-Associated Non-Hodgkin’s Lymphoma.” International Journal of Cancer. 106 (2003): 283–287.
Ferber D. Monkey virus links to cancer grow stronger. Science. 2002;296:1012-1015.
Ferber, D. “Creeping Consensus on SV40 and Polio Vaccine.” Science. 298 (2002): 725–727.
Fraumeni Jr., J. F., C. R. Stark, E. Gold, and M. L. Lepow. “Simian Virus 40 in Polio Vaccine: Follow-Up of Newborn Recipients.” Science. 167 (1970): 59–60.
Innis, M. D. “Oncogenesis and Poliomyelitis Vaccine.” Nature. 219 (1968): 972–973.
Mortimer, E. A., M. L. Lepow, E. Gold, et al. “Long-Term Follow-Up of Persons Inadvertently Inoculated with SV40 as Neonates.” New England Journal of Medicine. 305 (1981): 1517–1518.
Olin, P. and J. Giesecke. “Potential Exposure to SV40 in Polio Vaccines Used in Sweden during 1957: No Impact on Cancer Incidence Rates 1960 to 1993.” Development of Biological Standards. 94 (1998): 227–233.
Rollison, D. E. M., W. F. Page, H. Crawford, et al. “Case-Control Study of Cancer Among U.S. Army Veterans Exposed to Simian Virus 40-Contaminated Adenovirus Vaccine.” American Journal of Epidemiology. 160 (2004): 317–324.
Shah, K. and N. Nathanson. “Human Exposure to SV40: Review and Comment.” American Journal of Epidemiology 103 (1976): 1–12.
Shah, K. V., H. L. Ozer, H. S. Pond, et al. “SV40 Neutralizing Antibodies in Sera of U.S. Residents without History of Polio Immunization.” Nature. 231 (1971): 448–449.
Stenton, S. C. “Simian Virus 40 and Human Malignancy.” British Medical Journal 316 (1998): 877.
Strickler, H. D. and J. J. Goedert. “Exposure to SV40-Contaminated Poliovirus Vaccine and the Risk of Cancer: A Review of the Epidemiologic Evidence.” Development of Biological Standards. 94 (1998): 235–244.
Strickler, H. D., P. S. Rosenberg, S. S. Devesa, et al. “Contamination of Poliovirus Vaccines with Simian Virus 40 (1955–1963) and Subsequent Cancer Rates.” Journal of the American Medical Association. 279 (1998): 292–295.
Strickler, H. D., P. S. Rosenberg, S. S. Devesa, et al. “Contamination of Poliovirus Vaccine with SV40 and the Incidence of Medulloblastoma.” Medical and Pediatric Oncology. 32 (1999): 77–78.
Sweet, B. H. and M. R. Hilleman. “The Vacuolating Virus, S.V.40 (26128).” Proc Soc Exp Biol and Med. 105 (1960): 420-427.
Vilchez, R. A., A. S. Arrington, and J. S. Butel. “Cancer Incidence in Denmark Following Exposure to Poliovirus Vaccine Contaminated with Simian Virus 40.” Journal of the National Cancer Institute. 95 (2003): 1249.
Reviewed by Paul A. Offit, MD, on September 15, 2026